Filomena Cetani

List of Publications by Year
in descending order

146 papers	6,305 citations	87888 38 h-index	74163 75 g-index
162 all docs	162 docs citations	162 times ranked	5284 citing authors

#	Article	IF	Citations
1	Renal complications and quality of life in postsurgical hypoparathyroidism: a caseâ€“control study. Journal of Endocrinological Investigation, 2022, 45, 573-582.	3.3	12
2	Hypercalcemia due to CYP24A1 mutations: a systematic descriptive review. European Journal of Endocrinology, 2022, 186, 137-149.	3.7	17
3	Novel Glial Cells Missing-2 (GCM2) variants in parathyroid disorders. European Journal of Endocrinology, 2022, 186, 351-366.	3.7	12
4	European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). European Journal of Endocrinology, 2022, 186, R33-R63.	3.7	73
5	Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1â€“84) treatment. Journal of Endocrinological Investigation, 2022, 45, 1653-1662.	3.3	5
6	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. Nutrients, 2022, 14, 1742.	4.1	8
7	The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma. Frontiers in Endocrinology, 2022, 13, 869006.	3.5	6
8	Long-term Efficacy and Safety of Rifampin in the Treatment of a Patient Carrying a CYP24A1 Loss-of-Function Variant. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3159-e3166.	3.6	11
9	Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. Journal of Endocrinological Investigation, 2022, 45, 1909-1918.	3.3	7
10	Do the Heterozygous Carriers of a CYP24A1 Mutation Display a Different Biochemical Phenotype Than Wild Types?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 708-717.	3.6	11
11	Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?. Acta Haematologica, 2021, 144, 302-307.	1.4	4
12	Remission of Primary Hyperparathyroidism Following Fine-NeedleÂAspiration Biopsy: A Case Report and Review ofÂtheÂLiterature. AACE Clinical Case Reports, 2021, 7, 75-79.	1.1	3
13	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Endocrine-Related Cancer, 2021, 28, 111-134.	3.1	14
14	Pseudohypoparathyroidism: Focus on Cerebral and Renal Calcifications. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3005-e3020.	3.6	6
15	Effect of neridronate in osteopenic patients after heart, liver or lung transplant: a multicenter, randomized, double-blind, placebo-controlled study. Panminerva Medica, 2021, 63, 214-223.	0.8	5
16	Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4565-e4579.	3.6	7
17	Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis. Cancer Genomics and Proteomics, 2021, 18, 781-796.	2.0	9
18	Hypoparathyroidism and pseudohypoparathyroidism in pregnancy: an Italian retrospective observational study. Orphanet Journal of Rare Diseases, 2021, 16, 421.	2.7	5

#	Article	IF	Citations
19	Parathyroid Carcinoma and Ectopic Secretion of Parathyroid hormone. Endocrinology and Metabolism Clinics of North America, 2021, 50, 683-709.	3.2	5
20	Hypercalcemia. Endocrinology and Metabolism Clinics of North America, 2021, 50, xv-xvi.	3.2	0
21	Whole exome sequencing in familial isolated primary hyperparathyroidism. Journal of Endocrinological Investigation, 2020, 43, 231-245.	3.3	18
22	Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?. Journal of Endocrinological Investigation, 2020, 43, 677-682.	3.3	16
23	The Oncosuppressors <scp>MEN1</scp> and <scp>CDC73</scp> Are Involved in <scp>lncRNA</scp> Deregulation in Human Parathyroid Tumors. Journal of Bone and Mineral Research, 2020, 35, 2423-2431.	2.8	11
24	A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion. Case Reports in Endocrinology, 2020, 2020, 1-7.	0.4	3
25	Hypomagnesuria is Associated With Nephrolithiasis in Patients With Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2789-e2795.	3.6	12
26	Late-onset postsurgical hypoparathyroidism following parathyroidectomy for recurrent primary hyperparathyroidism: a case report and literature review. Endocrine, 2020, 69, 402-409.	2.3	0
27	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1581-1588.	3.6	27
28	Day case parathyroidectomy: is this the right way for the patients?. Gland Surgery, 2020, 9, S6-S13.	1.1	3
29	A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature. Endocrine, 2020, 67, 466-472.	2.3	2
30	Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT). European Journal of Endocrinology, 2019, 181, P1-P19.	3.7	61
31	Hereditary Hypercalcemia Caused by a Homozygous Pathogenic Variant in theCYP24A1Gene: A Case Report and Review of the Literature. Case Reports in Endocrinology, 2019, 2019, 1-7.	0.4	17
32	Acute severe primary hyperparathyroidism: spontaneous remission after 2Âyears follow-up. Journal of Endocrinological Investigation, 2019, 42, 243-244.	3.3	2
33	Familial and Hereditary Forms of Primary Hyperparathyroidism. Frontiers of Hormone Research, 2019, 51, 40-51.	1.0	36
34	Parathyroid Carcinoma. Frontiers of Hormone Research, 2019, 51, 63-76.	1.0	63
35	Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocrine-Related Cancer, 2019, 26, R441-R464.	3.1	87
36	A patient with MEN1 and endâ€‘stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation. Molecular and Clinical Oncology, 2018, 8, 449-452.	1.0	0

#	Article	IF	Citations
37	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. Calcified Tissue International, 2018, 103, 151-163.	3.1	23
38	Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism. Journal of Endocrinological Investigation, 2018, 41, 1221-1226.	3.3	40
39	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. Endocrine, 2018, 62, 215-233.	2.3	21
40	Clinical presentation and management of patients with primary hyperparathyroidism in Italy. Journal of Endocrinological Investigation, 2018, 41, 1339-1348.	3.3	32
41	Acute pancreatitis as the first manifestation in a young boy with primary hyperparathyroidism. Endocrine, 2018, 62, 267-268.	2.3	0
42	Thyrotoxicosis; Treatment. , 2018, , 673-679.		0
43	Clinical profile of juvenile primary hyperparathyroidism: a prospective study. Endocrine, 2018, 59, 344-352.	2.3	6
44	Parathyroid carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 877-889.	4.7	70
45	Non-surgical management of primary hyperparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 821-835.	4.7	19
46	Vitamin D measurement and effect on outcome in a cohort of patients with heart failure. Endocrine Connections, 2018, 7, 957-964.	1.9	15
47	The aberrantly expressed miR-372 partly impairs sensitivity to apoptosis in parathyroid tumor cells. Endocrine-Related Cancer, 2018, 25, 761-771.	3.1	17
48	Parathyroid carcinoma: a clinical and genetic perspective. Minerva Endocrinology, 2018, 43, 144-155.	1.1	20
49	Thyrotoxicosis; Systemic Manifestations. , 2018, , 665-672.		0
50	Development of an algorithm to predict serum vitamin D levels using a simple questionnaire based on sunlight exposure. Endocrine, 2017, 55, 85-92.	2.3	7
51	Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism. Endocrine, 2017, 55, 256-265.	2.3	42
52	Loss of p27 expression is associated with MEN1 gene mutations in sporadic parathyroid adenomas. Endocrine, 2017, 55, 386-397.	2.3	42
53	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine, 2017, 58, 349-359.	2.3	77
54	Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations. Journal of Surgical Oncology, 2017, 116, 1197-1199.	1.7	4

#	Article	IF	Citations
55	Novel association of MEN1 gene mutations with parathyroid carcinoma. Oncology Letters, 2017, 14, 23-30.	1.8	16
56	Expression, function, and regulation of the embryonic transcription factor TBX1 in parathyroid tumors. Laboratory Investigation, 2017, 97, 1488-1499.	3.7	25
57	Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS ONE, 2017, 12, e0186485.	2.5	31
58	Familial hypocalciuric hypercalcemia type 1 due to a novel homozygous mutation of the calcium-sensing receptor gene. Journal of Endocrinological Investigation, 2017, 40, 1271-1272.	3.3	4
59	Update on parathyroid carcinoma. Journal of Endocrinological Investigation, 2016, 39, 595-606.	3.3	98
60	A large functioning parathyroid lipoadenoma. Endocrine, 2016, 53, 615-616.	2.3	6
61	A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule. World Journal of Surgical Oncology, 2015, 13, 270.	1.9	18
62	Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4. Endocrine Connections, 2015, 4, 1-8.	1.9	44
63	Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocrine Connections, 2015, 4, 172-178.	1.9	37
64	Parathyroid Carcinoma. , 2015, , 409-421.		6
65	Rare diseases in clinical endocrinology: a taxonomic classification system. Journal of Endocrinological Investigation, 2015, 38, 193-259.	3.3	11
66	Increased Prevalence of theGCM2Polymorphism, Y282D, in Primary Hyperparathyroidism: Analysis of Three Italian Cohorts. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2794-E2798.	3.6	18
67	First evidence of <scp>TRPV</scp>5 and <scp>TRPV</scp>6 channels in human parathyroid glands: possible involvement in neoplastic transformation. Journal of Cellular and Molecular Medicine, 2014, 18, 1944-1952.	3.6	12
68	Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB). Journal of Endocrinological Investigation, 2014, 37, 149-165.	3.3	12
69	The use of positron emission tomography with 11C-methionine in patients with primary hyperparathyroidism. Endocrine, 2013, 43, 251-252.	2.3	5
70	Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutations Occur Rarely in Sporadic Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2800-2810.	3.6	29
71	Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clinical Endocrinology, 2013, 79, 20-26.	2.4	32
72	CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocrine Connections, 2013, 2, 186-195.	1.9	76

#	Article	IF	Citations
73	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. PLoS Genetics, 2013, 9, e1003350.	3.5	125
74	Cinacalcet in the management of primary hyperparathyroidism. Expert Review of Endocrinology and Metabolism, 2012, 7, 45-53.	2.4	6
75	The microRNA cluster C19MC is deregulated in parathyroid tumours. Journal of Molecular Endocrinology, 2012, 49, 115-124.	2.5	89
76	Bone disease in primary hyperparathyrodism. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 357-368.	2.7	43
77	Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association?. BMC Cancer, 2012, 12, 614.	2.6	5
78	Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2. Journal of Oncology, 2012, 2012, 1-15.	1.3	79
79	Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. Journal of Endocrinological Investigation, 2012, 35, 655-60.	3.3	25
80	Update on the use of cinacalcet in the management of primary hyperparathyroidism. Journal of Endocrinological Investigation, 2012, 35, 90-5.	3.3	9
81	High-intensity focused ultrasound as an alternative to the surgical approach in primary hyperparathyroidism: A preliminary experience. Journal of Endocrinological Investigation, 2011, 34, 655-659.	3.3	19
82	Primary Hyperparathyroidism. New England Journal of Medicine, 2011, 365, 2389-2397.	27.0	312
83	A proteomic approach to study parathyroid glands. Molecular BioSystems, 2011, 7, 687-699.	2.9	24
84	Evaluation of formalin-fixed paraffin-embedded tissues in the proteomic analysis of parathyroid glands. Proteome Science, 2011, 9, 29.	1.7	25
85	Somatostatin Analogues do not Aff ect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome. Hormone and Metabolic Research, 2011, 43, e1-e1.	1.5	0
86	A novel mutation in the calcium-sensing receptor in a French family with familial hypocalciuric hypercalcaemia. European Journal of Endocrinology, 2011, 165, 359-363.	3.7	4
87	Somatostatin Analogues do not Affect Calcium Metabolism in Patients with Acromegaly and Primary Hyperparathyroidism due to MEN 1-Like Syndrome. Hormone and Metabolic Research, 2011, 43, 126-129.	1.5	0
88	Molecular pathogenesis of primary hyperparathyroidism. Journal of Endocrinological Investigation, 2011, 34, 35-9.	3.3	13
89	Persistent secondary hyperparathyroidism and vertebral fractures in kidney transplantation: Role of calcium-sensing receptor polymorphisms and vitamin D deficiency. Journal of Bone and Mineral Research, 2010, 25, 841-848.	2.8	51
90	Î²-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. Endocrine-Related Cancer, 2010, 17, 1-6.	3.1	54

#	Article	IF	Citations
91	Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. Journal of Experimental Medicine, 2010, 207, 299-308.	8.5	593
92	The Sulfaphenazole-Sensitive Pathway Acts as a Compensatory Mechanism for Impaired Nitric Oxide Availability in Patients with Primary Hyperparathyroidism. Effect of Surgical Treatment. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 920-927.	3.6	22
93	Morphometric Vertebral Fractures in Postmenopausal Women with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2306-2312.	3.6	170
94	Identification and functional characterization of loss-of-function mutations of the calcium-sensing receptor in four Italian kindreds with familial hypocalciuric hypercalcemia. European Journal of Endocrinology, 2009, 160, 481-489.	3.7	8
95	Parathyroid Carcinoma. , 2009, , 321-333.		2
96	Parathyroid Carcinoma. Journal of Bone and Mineral Research, 2008, 23, 1869-1880.	2.8	243
97	Re: Familial hyperparathyroidism: Surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery, 2008, 144, 839-840.	1.9	22
98	Terapia medica dellâ€™iperparatiroidismo primario. L Endocrinologo, 2008, 9, 54-61.	0.0	0
99	Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment. Journal of Endocrinological Investigation, 2008, 31, 900-904.	3.3	21
100	Autoantibodies against Type I Interferons as an Additional Diagnostic Criterion for Autoimmune Polyendocrine Syndrome Type I. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4389-4397.	3.6	176
101	HRPT2gene analysis and the diagnosis of parathyroid carcinoma. Expert Review of Endocrinology and Metabolism, 2008, 3, 377-389.	2.4	4
102	Parafibromin as a Tool for the Diagnosis of Parathyroid Tumors. Advances in Anatomic Pathology, 2008, 15, 179.	4.3	8
103	Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocrine-Related Cancer, 2007, 14, 493-499.	3.1	38
104	Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?. European Journal of Endocrinology, 2007, 156, 547-554.	3.7	144
105	Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3114-3121.	3.6	347
106	The impact of thyroidectomy on parathyroid glands: A biochemical and clinical profile. Journal of Endocrinological Investigation, 2007, 30, 666-671.	3.3	13
107	Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clinical Endocrinology, 2006, 64, 146-152.	2.4	59
108	Microvessel Density in Human Normal and Neoplastic Parathyroids. Endocrine Pathology, 2006, 17, 175-182.	9.0	8

#	Article	IF	Citations
109	The reduction of bone mineral density in postmenopausal women with primary hyperparathyroidism is higher in the presence of concomitant GH secretion impairment. European Journal of Endocrinology, 2006, 155, 41-45.	3.7	2
110	Genetic Analyses of theHRPT2Gene in Primary Hyperparathyroidism: Germline and Somatic Mutations in Familial and Sporadic Parathyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5583-5591.	3.6	234
111	TSH receptor antibodies do not alter the function of gonadotropin receptors stably expressed in eukaryotic cells. European Journal of Endocrinology, 2004, 150, 381-387.	3.7	7
112	A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clinical Endocrinology, 2004, 60, 99-106.	2.4	67
113	A novel germline mutation of MEN 1 gene in a patient with acromegaly and multiple endocrine tumors. Journal of Endocrinological Investigation, 2004, 27, 577-582.	3.3	4
114	Spontaneous short-term remission of primary hyperparathyroidism from infarction of a parathyroid adenoma. Journal of Endocrinological Investigation, 2004, 27, 687-690.	3.3	16
115	Two Italian kindreds with familial hypocalciuric hypercalcaemia caused by loss-of-function mutations in the calcium-sensing receptor (CaR) gene: functional characterization of a novel CaR missense mutation. Clinical Endocrinology, 2003, 58, 199-206.	2.4	27
116	Impaired GH secretion to provocative stimuli in two families with hypocalciuric hypercalcaemia. Clinical Endocrinology, 2003, 59, 604-606.	2.4	6
117	Familial Hypocalciuric Hypercalcemia in a Woman with Metastatic Breast Cancer: A Case Report of Mistaken Identity. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5132-5136.	3.6	13
118	Calcium-sensing receptor gene polymorphism is not associated with bone mineral density in Italian postmenopausal women. European Journal of Endocrinology, 2003, 148, 603-607.	3.7	16
119	A quick intraoperative parathyroid hormone assay in the surgical management of patients with primary hyperparathyroidism: a study of 206 consecutive cases. European Journal of Endocrinology, 2002, 146, 783-788.	3.7	95
120	Ipocalcemie. L Endocrinologo, 2002, 3, 3-14.	0.0	0
121	Calcium-sensing receptor gene polymorphisms in primary hyperparathyroidism. Journal of Endocrinological Investigation, 2002, 25, 614-619.	3.3	31
122	MEN1 gene alterations do not correlate with the phenotype of sporadic primary hyperparathyroidism. Journal of Endocrinological Investigation, 2002, 25, 508-512.	3.3	8
123	Genetic analysis of the MEN1 gene and HPRT2 locus in two Italian kindreds with familial isolated hyperparathyroidism. Clinical Endocrinology, 2002, 56, 457-464.	2.4	32
124	A Novel Mutation of the Autoimmune Regulator Gene in an Italian Kindred with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, Acting in a Dominant Fashion and Strongly Cosegregating with Hypothyroid Autoimmune Thyroiditis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4747-4752.	3.6	170
125	A Novel Mutation of the Autoimmune Regulator Gene in an Italian Kindred with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy, Acting in a Dominant Fashion and Strongly Cosegregating with Hypothyroid Autoimmune Thyroiditis. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4747-4752.	3.6	33
126	Six novelMEN1 gene mutations in sporadic parathyroid tumors. Human Mutation, 2000, 16, 445-445.	2.5	14

#	Article	IF	Citations
127	Parathyroid Expression of Calcium-Sensing Receptor Protein andin VivoParathyroid Hormone-Ca²⁺Set-Point in Patients with Primary Hyperparathyroidism¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4789-4794.	3.6	70
128	Six novel MEN1 gene mutations in sporadic parathyroid tumors Communicated by: Richard G.H. Cotton Online Citation: Human Mutation, Mutation in Brief #373 (2000) Online http://journals.wiley.com/1059-7794/pdf/mutation/373.pdf. Human Mutation, 2000, 16, 445.	2.5	6
129	Parathyroid Expression of Calcium-Sensing Receptor Protein and in Vivo Parathyroid Hormone-Ca2+ Set-Point in Patients with Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 4789-4794.	3.6	61
130	A new mutation of the MEN1 gene in an italian kindred with multiple endocrine neoplasia type 1. European Journal of Endocrinology, 1999, 140, 429-433.	3.7	19
131	No Evidence for Mutations in the Calcium-Sensing Receptor Gene in Sporadic Parathyroid Adenomas. Journal of Bone and Mineral Research, 1999, 14, 878-882.	2.8	98
132	Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. Journal of Endocrinological Investigation, 1999, 22, 273-278.	3.3	27
133	Hyperfunctioning Thyroid Nodules in Toxic Multinodular Goiter Share Activating Thyrotropin Receptor Mutations with Solitary Toxic Adenoma¹. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 492-498.	3.6	82
134	Specific activation of the thyrotropin receptor by trypsin. Molecular and Cellular Endocrinology, 1996, 119, 161-168.	3.2	73
135	Differential effects of NaCl concentration on the constitutive activity of the thyrotropin and the luteinizing hormone/chorionic gonadotropin receptors. FEBS Letters, 1996, 378, 27-31.	2.8	75
136	Oncogenic mutations in thyroid adenoma: methodological criteria. European Journal of Endocrinology, 1996, 135, 444-446.	3.7	15
137	Functional Characteristics of a Variant Thyrotropin Receptor. FEBS Journal, 1996, 238, 490-494.	0.2	13
138	TSH receptor and disease. Clinical Endocrinology, 1996, 44, 621-633.	2.4	78
139	Patient with monoclonal gammopathy, thyrotoxicosis, pretibial myxedema and thyroid-associated ophthalmopathy; demonstration of direct binding of autoantibodies to the thyrotropin receptor. European Journal of Endocrinology, 1996, 134, 97-103.	3.7	21
140	Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 547-554.	3.6	128
141	Mapping thyroid peroxidase epitopes using recombinant protein fragments. European Journal of Endocrinology, 1995, 132, 53-61.	3.7	35
142	The thyroperoxidase doublet is not produced by alternative splicing. Molecular and Cellular Endocrinology, 1995, 115, 125-132.	3.2	10
143	Post-surgical follow-up of differentiated thyroid cancer. Journal of Endocrinological Investigation, 1995, 18, 165-166.	3.3	12
144	Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal of Surgery, 1994, 18, 600-604.	1.6	164

#	Article	IF	Citations
145	Thyroid Ultrasonography Helps to Identify Patients with Diffuse Lymphocytic Thyroiditis who Are Prone to Develop Hypothyroidism*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 209-213.	3.6	267
146	Assays of TSH-Receptor Antibodies in 576 Patients with Various Thyroid Disorders: Their Incidence, Significance and Clinical Usefulness. Autoimmunity, 1989, 3, 103-112.	2.6	20